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Abstract
Background: Peritoneal metastases are often reported in several abdominal tumors. Peritoneal diffusion from extra-
abdominal tumors is thought to be rare. Lung cancer is one of the most common cancers in the world with early
metastases and it is associated with poor prognosis in advanced stages. Peritoneal metastases from lung cancer are
uncommon and the real mechanism of its diffusion to the peritoneum is unknown. However, its clinical behavior is
similar to any other peritoneal metastasis from abdominal tumors.
Case presentation: We present two Caucasian patients (a 44-year-old man and a 59-year-old man) with bowel
obstruction from peritoneal metastases from non-small cell lung cancer who successfully underwent emergency
cytoreductive surgery and had a good prognosis and survival.
Conclusions: In our patients with isolated peritoneal metastases from lung cancer, cytoreduction showed good
prognosis with acceptable morbidity. This treatment option might be considered in highly selected cases to improve
survival. Strict follow-up is mandatory to allow early diagnosis of peritoneal diffusion.
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Background
The occurrence of peritoneal metastases represents the
clinical final stage of several tumors: most commonly
ovarian, colorectal, gastric cancers, and, less frequently,
appendix cancer. In recent years, the inclusion of cytore-
ductive surgery, alone or associated with locoregional
chemotherapy, in the treatment strategy of some of
these conditions has increased (peritoneal metastases
from ovarian cancer or primary peritoneal malignancies),
whereas its application remains mainly investigational in
other conditions (gastric, colorectal, endometrial, and
breast cancers) [1, 2].
Lung cancer is one of the most common cancers
worldwide. It is the leading cause of death from cancer;
diagnosis is often made at an advanced stage when
metastases have already spread to the other lung, to the
liver, to the brain, to the bone, and to adrenal glands [3].
Few reports are available in the literature about patients
with peritoneal metastases from lung cancer [4–6]. Des-
pite any treatment, overall survival for these patients is
very poor, with reported rates of 9months in a recent
series [5].
We describe two cases of diffused peritoneal metasta-
ses from lung cancer who underwent emergency cytore-
ductive surgery for bowel occlusion and had an
unexpectedly good prognosis and long-term survival.
Cases presentation
Patient 1
In March 2013, a 44-year-old Caucasian man, a non-smoker
of tobacco, was referred to our department as an emergency
with 3 days’ history of bowel obstruction. His family history
was negative for cancer. His past medical history included a
right pneumonectomy in 2009 for a T2, N1, M0G3, stage
IIB lung adenocarcinoma. Immunohistochemistry was
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positive for cytokeratin 7 and negative for thyroid transcrip-
tion factor 1 (TTF-1), caudal type homeobox transcription
factor 2 (CDX2), cytokeratin 20, protein S100, thyroglobulin,
the anti-melanosome clone, human melanoma black 45
(HMB-45), and the anti-melanoma, melanoma antigen rec-
ognized by T cells 1 (MART-1). After surgery, he underwent
four cycles of adjuvant chemotherapy with cisplatin (100
mg/m2) and paclitaxel (175mg/m2); he then received two
cycles of gemcitabine (1000mg/m2) after the fourth cycle of
cisplatin and paclitaxel for a grade 4 toxicity to paclitaxel.
On admission in our department, he was off any treatment,
and 1 month previously he had negative magnetic resonance
imaging (MRI) for brain metastases. His vital signs were
normal. Performance status assessed by the Eastern Co-
operative Oncologic Group (ECOG) [7] was 1. He had been
vomiting and his bowel had been obstructed for 24 hours. A
clinical examination revealed a tender distended abdomen.
Blood tests were normal except for neutrophilic
leukocytosis: white blood cells (WBC) 14,000/mm3.
Neuron-specific enolase and cytokeratin-19 fragment
(CYFRA 21-1) levels were normal (respectively 121 ng/ml
and < 3 ng/ml). A total body contrast-enhanced computed
tomography (CT) scan showed a distended large bowel with
air-fluid levels and multiple neoplastic implants involving
the right colon, greater omentum, spleen, and the sigmoid
colon, ranging from 0.5 to 10 cm. (Fig. 1). No other patho-
logical findings were disclosed and a chest examination was
negative except for the outcomes of the previous thoracic
surgery (Fig. 2).
Considering his young age, the absence of lung recur-
rence and of any other distant metastasis, palliative sur-
gery was considered in order to treat bowel obstruction.
At laparotomy there was no ascites, and three gross neo-
plastic implants were found in the greater omentum,
right colonic flexure, transverse colon, and left colon.
Extensive cytoreductive surgery was performed and sur-
gical procedures included subtotal colectomy with ileo-
sigmoid anastomosis, splenectomy, and greater
omentectomy (Figs. 3 and 4). At the end of the proced-
ure no residual macroscopic disease was left, reaching a
completeness of cytoreduction score (CCS) of 0.
Pathology showed complete infiltration of the colonic
wall and spleen by adenocarcinoma nodules with lymph
node metastases in the mesocolon.
Fig. 1 Coronal two-dimensional image showing huge implants
(arrows) of peritoneal metastases located near colonic splenic flexure
providing a compression of the lumen and in Morison pouch between
right kidney and right liver
Fig. 2 Axial two-dimensional image obtained after intravenous
administration of iodinated contrast agent, showing outcomes of
right pneumonectomy (arrow)
Fig. 3 Intraoperative picture showing gross neoplastic implants on
greater omentum, transverse colon, and left colon (arrows)
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Immunohistochemistry evaluation showed the same
staining as the previous lung adenocarcinoma, confirm-
ing the lung origin of the peritoneal metastases.
His postoperative course was complicated by fever
(38.5 °C) and dyspnea on postoperative day 9. A chest X-
ray showed a “ground glass” picture of left lung and
bloodstream and expectorate cultures were positive for
Candida albicans species. Intravenously administered
anidulafungin treatment was started with rapid improve-
ment of our patient’s general condition and gradual reso-
lution of sepsis. He was discharged on postoperative day
20 and subsequently he underwent six cycles of adjuvant
chemotherapy with cisplatin (100 mg/m2). Considering
the previous toxicity to paclitaxel no other drug was
used. A follow-up protocol included clinical evaluation
(1 month after surgery, then every 3 months), blood
tests with tumor marker levels every 3 months, and total
body CT scan 1 month after surgery, then every 3
months for the first year and every 6 months for the
next 2 years. Yearly, a brain MRI was scheduled. He was
alive and disease free 3 years after surgery. In September
2016 he was lost to follow-up.
Patient 2
In September 2011, a 59-year-old Caucasian man, a
heavy tobacco smoker, presented to our department as
an emergency with abdominal pain and vomiting. His
past medical history included a left upper lobectomy for
a T1N1M0, G3 stage IIB lung adenocarcinoma (3 years
before) followed by six cycles of systemic chemotherapy
(carboplatin + paclitaxel 175 mg/m2). His family history
was positive for cancer (a 39-year-old brother died of
colon cancer). Two days before admission, abdominal
distension and bowel obstruction occurred and progres-
sively worsened. His WBC count was 18,000/mm3. A
total body CT scan showed a large mass involving the
distal ileal loops with obstruction and distension of the
proximal bowel, with a small amount of ascites in his
pelvis.
He underwent explorative laparoscopy that confirmed
the CT scan findings, showing no other peritoneal seed-
ing. Ascites was taken for cytological examination, and a
laparoscopic ileocolic resection with ileotransverse anas-
tomosis was performed, reaching a CCS of 0. His post-
operative course was uneventful and he was discharged
on postoperative day 4. Pathology confirmed the diagno-
sis of metastasis from adenocarcinoma; ascites was
found to be negative for neoplastic cells. At immunohis-
tochemistry, cancer cells were positive for cytokeratin 7
and TTF-1 confirming the origin of peritoneal metasta-
ses from the lung cancer. He was followed by medical
oncologists and, due to his poor general condition, he
underwent a second-line adjuvant chemotherapy with
gemcitabine only (1000 mg/m2). He was disease free for
2 years. Subsequently, brain metastases occurred and in
February 2014 he died (Table 1).
Discussion
Overall median survival in metastatic lung cancer is very
poor. In recent studies it ranged between 3 and 12
months, depending on type of treatment [8]. Peritoneal
metastases from extra-abdominal cancers are rare and
have a poor prognosis. In a recent large population study
by Flanagan et al., the overall incidence rate of periton-
eal metastases from extra-abdominal cancers was 9%,
mostly originating from breast cancer (40.8%), followed
by lung cancer (25.6%), and melanoma (9.5%) [5]. Satoh
et al. reported a rate of 1.2% of peritoneal metastases
complicating the clinical course of advanced lung cancer
[9], while in other autopsy series this rate was found to
be 12% [10]. Therefore, it could be argued that a number
of cases of peritoneal metastases remains undiagnosed
or unreported in patients with lung cancer. A few stud-
ies reported isolated bowel metastases from non-small
cell lung carcinoma (NSCLC) with very poor prognosis
[4, 9, 10] and some others described the peritoneal diffu-
sion of pleural mesothelioma [11, 12].
In gastrointestinal tumors, peritoneal metastases gen-
erally arise either from direct invasion of the bowel wall
or from cancer cells spilled by surgical manipulation
[13]. These mechanisms are not applicable to lung can-
cer. In stage IV lung cancer, pleural metastases at diag-
nosis are significantly associated with subsequent
peritoneal spread, whereas no association between onco-
gene status and peritoneal disease has been reported [6].
Pleural serosa infiltration might eventually explain the
peritoneal seeding, but this mechanism could not be
considered in our cases since our patients had no pleural
disease.
Fig. 4 Final surgical specimen showing gross neoplastic implants
involving right side of colon, transverse colon, left colon, greater
omentum, and splenic flexure (arrows)
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According to the two most recent systematic reviews,
bowel obstruction is the most frequent clinical presen-
tation although bleeding and perforation are also re-
ported [14, 15]. CT and positron emission tomography
(PET) scans are useful tools for diagnosis in the late
stages, while CT scan sensitivity is low at the early stage
of peritoneal diffusion. In most patients, the time inter-
val between primary lung cancer and peritoneal metas-
tases ranges from 2 months to 4 years. The most
frequent histology is NSCLC, with large cell cancer and
adenocarcinoma being the most common subtypes. The
prognosis for patients with peritoneal metastases from
lung cancer is very poor regardless of the treatment,
with a median survival rate of 2 to 4 months. In a re-
cent review, Balla et al. found two cases of peritoneal
metastases out of a sample of 91 patients with lung
cancer with gastrointestinal metastases: the disparity
with autopsy series suggests that most cases are asymp-
tomatic or unreported [16, 17]. Emergency surgery for
bowel obstruction and extra-abdominal metastases,
found in up to 60% of patients [11, 12], could be the
main reasons for the poor prognosis. However, the pa-
tients reported in this study had an unexpected good
outcome despite their emergency presentation and the
presence of diffused peritoneal involvement in one of
them. They reached, respectively, 3-year and 2-year dis-
ease-free survival and one of them is currently alive.
The absence of extra-abdominal metastases might per-
haps explain the unexpected long survival. However,
our results suggest that a combined approach (surgery
and chemotherapy) could be advocated in selected pa-
tients with peritoneal metastases from lung cancer with
some survival advantages compared to standard
treatment. Cytoreductive surgery combined with hyper-
thermic intraperitoneal chemotherapy (HIPEC) in un-
conventional indications is occasionally reported in
experienced tertiary centers [2], most frequently from
rare ovarian cancers, sarcoma, or neuroendocrine tu-
mors, and, more rarely, from gastrointestinal stromal
tumor (GIST), hepatocellular and cholangiocarcinoma
and desmoplastic small round cell tumors. The gap
existing between the small reported series data and the
incidence rates in autopsy series could suggest that in
most cases peritoneal metastases from lung cancer re-
main clinically silent [16]. Our results on these two pa-
tients might help in stimulating more awareness of this
condition and in suggesting a strict follow-up: in fact,
early diagnosis of peritoneal diffusion, which is prob-
ably often underrated, could allow a radical cytoreduc-
tive surgery providing some advantages to survival.
Considering the behavior of lung cancer, in particular,
its tendency to early metastases because of its continu-
ous dynamic state and large blood and lymphatic supply
that spreads a large amount of neoplastic cells directly
in the bloodstream [18], the association of a strict fol-
low-up and focused imaging techniques could help to
identify selected cases to be treated, avoiding emergency
“salvage” treatments that are difficult to perform even in
dedicated centers.
High postoperative morbidity should be carefully
considered when an extensive surgical treatment is
planned on a patient with an advanced oncological
stage. In our small series of two patients no major
complications were observed, and maximal cytoreduc-
tion and HIPEC should not be discarded a priori as a
treatment option. Further studies on this specific
Table 1 Key features of the patients
Patient 1 Patient 2
Age (years) 44 59
Sex M M
Primary lung cancer T2 N1 M0 NSCLC T1 N1 M0 NSCLC
Previous thoracic
surgery
Right pneumonectomy Left upper lobectomy
Previous adjuvant
chemotherapy
Four cycles intravenously administered 100mg/m2 cisplatin + 175mg/m2 Taxol
(paclitaxel) and Two cycles intravenously administered 1000mg/m2 gemcitabine
Six cycles intravenously administered
carboplatin + 175mg/m2 paclitaxel
Clinical
presentation
Bowel obstruction Bowel obstruction
Surgical
procedure
Subtotal colectomy, splenectomy, omentectomy Laparoscopic ileocolic resection
CCS 0 (no residual disease) 0 (no residual disease)
Adjuvant chemo Six cycles intravenously administered 100mg/m2 cisplatin Intravenously administered 1000 mg/m2
gemcitabine
Follow-up Alive disease free Died brain metastases
Survival (months) 36 25
CCScompleteness of cytoreduction score, M male, NSCLC non-small cell lung carcinoma
Sibio et al. Journal of Medical Case Reports          (2019) 13:262 Page 4 of 5
subset of patients could better clarify indications and
limits.
Conclusions
In our patients with isolated peritoneal metastases from
lung cancer, cytoreduction showed good prognosis with
acceptable morbidity. Although resection is the standard
of care in bowel obstructions, this treatment option
might be considered even in an elective stetting in highly
selected cases to improve survival. Strict clinical and im-
aging diagnostic follow-up should be performed in these
patients, and a peritoneal diffusion of the tumor should
be anticipated and investigated.
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